Personalized prediction for ulcerative colitis treatment response
Part of Digestive system clinical trials.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of ulcerative colitis (based on symptoms, scope findings, and biopsy results).
- You are scheduled to start one of these treatments: vedolizumab, ustekinumab, or tofacitinib.
- You (and your family history) are Korean ethnicity.
- Your condition is classified as ulcerative colitis (not “inflammatory bowel disease unclassified”).
- You have not already had surgery to remove the colon because of ulcerative colitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This trial tests whether vedolizumab helps people with moderate-to-severe ulcerative colitis and what changes happen in the gut microbiome (the community of helpful bacteria in your intestines). You may be able to join if you’re an adult with ulcerative colitis who has not used vedolizumab before and haven’t taken certain gut-affecting medicines recently.
This study tries to better predict how an ulcerative colitis flare will progress by using a mix of your medical information. If you are eligible, your flare details may help researchers build tools that guide future care.
This study tests whether adding a special probiotic (VSL#3) to vedolizumab helps people with moderate ulcerative colitis more than vedolizumab alone. You may qualify if you are already planning to start vedolizumab and haven't responded well enough to other treatments.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.